Redeye regards today’s presented interim data of AP1189 in rheumatoid arthritis as encouraging from both a safety and a potential efficacy point of view. However, we also recognize the low patient sample (n=12), and the fact that it is hard to draw any conclusions from blinded data. We choose to keep our Base case valuation of SEK 17 until more data from the Phase II trial becomes available.